You are here: Industry Insights > MHRA

News List

Early risers: life-changing medical scheme given legal revitalisation pharmatimes
February 03, 2022
Boost for patients with life-threatening conditions who require access to medicines not yet authorised for marketing.
Voxelotor for haemolytic anaemia treatment gains positive opinion pharmatimes
January 27, 2022
MHRA awards a positive scientific opinion for voxelotor–a once-daily tablet for the treatment of haemolytic anaemia.
UK MHRA grants approval to Pfizer’s oral antiviral for Covid-19 Pharmaceutical-Technology
January 04, 2022
In a trial, Paxlovid, given within three days of symptom onset, lowered hospitalisation and death risk within 28 days by 89%.
MHRA grants approval for Pfizer’s oral COVID-19 antiviral pill pharmatimes
January 04, 2022
Pfizer’s Paxlovid has a success rate of nearly 90% as a prophylaxis treatment against severe COVID-19 when administered shortly after the patient has been infected with the virus.
COVID-19 vaccine should be offered to vulnerable children aged five to 11-years-old pharmatimes
December 23, 2021
Government vaccine advisers have said vulnerable primary school children should be offered a low-dose of a COVID-19 vaccine.
Northwest Biotherapeutics Receives MHRA Approval of License for GMP Manufacturing in UK contractpharma
December 22, 2021
Enables the manufacturing of DCVax-L products to get under way at the Sawston facility.
UK regulator publishes guidance on use of real-world data to support clinical trials EuropeanPharmaceuticalReview
December 20, 2021
Two new guidance documents, the first in a series to published by the MHRA, outline considerations when planning a randomised clinical trial using real-world data.
Health minister welcomes new treatments for COVID-19 patients PharmaTimes
December 13, 2021
The treatments are being offered as an addition to vaccinations to maximise protection against COVID-19.
UK’s MHRA grants authorisation for GSK-Vir Biotechnology’s Covid-19 drug Pharmaceutical-Technology
December 06, 2021
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorisation for GSK and Vir Biotechnology’s investigational Covid-19 therapy, Xevudy (sotrovimab).
MHRA approves Xevudy (sotrovimab) to treat COVID-19 EuropeanPharmaceuticalReview
December 03, 2021
The Medicines and Healthcare products Regulatory Agency (MHRA) approve sotrovimab for people with mild to moderate COVID-19 infection and at least one risk factor for developing severe illness.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page